Roth Capital

The cannabis industry faces a rare opportunity as the drug heads toward a potential rescheduling in the United States. A new Roth Capital report suggests that multistate operators (MSOs) are the most promising companies in the space. The Analyst Roth Capital Partners analyst Scott Fortune said the...

Marchex, Inc. (NASDAQ: MCHX) has been undergoing a period of transformation and should become a growth business in 2019 and beyond, according to Roth Capital. The Analyst Roth Capital’s Darren Aftahi upgraded Marchex from Neutral to Buy and raised the price target from $3.40 to $7. The Thesis...

Sodastream International Ltd (NASDAQ: SODA) popped nearly 6 percent Wednesday after management reported fourth-quarter sales 5 percent above estimates. This marks SodaStream’s fifth consecutive positive quarter. The company has been on a 300-percent run since February 2016, when it saw long-...

Recro Pharma Inc (NASDAQ: REPH) shares are jumping on Monday after it announced positive top-line results from the second of the two late-stage trials of intra-venous meloxicam meant to treat acute post-operative pain. The Compound Meloxicam is long-acting preferential COX-2 inhibitor,...

First Solar, Inc. (NASDAQ: FSLR) bulls are enduring a frustrating trading session on Thursday. The stock is down 11.3 percent on the day following Q2 earnings and revenue beats. First Solar charged $86 million in Q2 when it decided to no longer make solar panels using TetraSun’s silicon...

MeetMe, Inc (NASDAQ: MEET) is up 9 percent since news of LinkedIn Corp (NYSE: LNKD)’s purchase by Microsoft Corporation (NASDAQ: MSFT). Other Internet/social media companies have risen also — Twitter Inc (NYSE: TWTR) is up 7.5 percent and Match Group Inc (NASDAQ: MTCH) of Match.com is...

Roth Capital has upgraded Aptose Biosciences Inc (NASDAQ: APTO) to Buy from Neutral "on an expected inflection point in the near-term, namely the allowance for APTO-253 to return to the clinical." Belonging to a new small molecules class, APTO-253 "is designed to induce a silent tumor-suppressive...

Roth Capital Partners analyst, Chris Lewis, believes that Biocept Inc (NASDAQ: BIOC) is an emerging leader in Liquid Biopsy. Therefore, he initiated coverage on the stock with a rate of Buy and kept a price tag of $1.20. The brokerage thinks that through its proprietary technology platform,...

Roth Capital has initiated coverage on Izea Inc (NASDAQ: IZEA) with a Buy rating and $9 price target, saying that the digital marketing company would benefit from millennial trends. Izea, with its agnostic platform, should capitalize on the ongoing millennial shift to mobile apps that has given...

On Thursday morning, TheStreetSweeper published a report providing seven reasons why Mitek Systems, Inc. (NASDAQ: MITK), which had almost doubled since the beginning of the year, is on the verge of a nosedive. Among the issues were insider sales, intellectual property, Mobile ID competition and...

Roth Capital has downgraded Synergy Resources Corp (NYSE: SYRG) to Neutral from Buy, saying its recent $505 million asset purchase deal will lead to additional share dilution. Synergy Resources agreed to buy 33,100 netacres in the core Wattenberg (72,000 gross) from Noble Energy, Inc. (NYSE: NBL)...

Like many small-cap biotech stocks, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) is no stranger to the rumor mill. StreetInsider reported the company was exploring a sale on April 8, sending shares 8 percent higher. Bloomberg reported a similar rumor in March 2015, also yielding no follow-through...